Ambit Biosciences Announces Participation at 12th Annual Biotechnology Industry Organization (BIO) Investor Forum
SAN DIEGO, Oct. 2, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the 12th Annual BIO Investor Forum to be held at the Palace Hotel in San Francisco, October 8-9, 2013.
Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, Quizartinib, at 2:30 p.m. PT/ 5:30 p.m. ET on Wednesday, October 9. The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com. An audio replay will be available for 30 days following the initial presentation webcast.
The 12th Annual BIO Investor Forum is an international investor conference focused on private and emerging public biotech companies. The BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.
About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.
Ambit Contacts: | |
Marcy Graham | Ian Stone/David Schull |
Executive Director, Investor Relations & Corp Comm | Media Contacts |
Ambit Biosciences, Inc. | Russo Partners |
858-334-2125 | 619-308-6541/212-845-4271 |
mgraham@ambitbio.com | ian.stone@russopartnersllc.com/david.schull@russopartnersllc.com |
SOURCE Ambit Biosciences
Help employers find you! Check out all the jobs and post your resume.